Fampharm A.D. Kruševac is a pharmaceutical manufacturing company in Serbia that became part of Tender Group’s portfolio during the mid-2000s expansion into the Serbian market
Originally a division of the famous Fabrika Maziva FAM (a lubricant and chemicals factory), Fampharm was established in the 1990s to produce pharmaceutical preparations in Kruševac . The facility and operations were privatized in 2006, when a consortium of investors acquired it at a public auction . Soon after, Tender Group emerged as the new majority owner, reflecting its strategy of reviving underutilized industrial assets.
Informations
Under Tender Group’s stewardship, Fampharm’s focus has been on revitalizing and updating the production of medications to modern standards. Plans were announced to construct a new pharmaceuticals factory in Kruševac, aiming to upgrade technologies and increase capacity for drug manufacturing. Key points about Fampharm include:
• Product Lines: Historically, Fampharm has been involved in producing generic medicines and pharmaceutical substances, possibly including analgesics, antiseptics, and other common drug formulations (e.g., codeine-based products, as indicated by research references sourcing Fampharm for compounds ). With Tender’s investment, the range and volume of products are expected to expand, targeting both domestic Serbian needs and export markets in the region.
• Facility Modernization: The initiative to build new production facilities is aimed at meeting EU Good Manufacturing Practice (GMP) standards. This involves installing advanced equipment for tablet pressing, capsule filling, solution mixing, and packaging, as well as quality control labs. By doing so, Fampharm can ensure high-quality output and potentially contract manufacture for international pharma companies.
• Strategic Synergies: Kruševac is also home to other Tender Group interests (such as the Novi Palas Hotel and a tobacco fermentation plant in Niš region), giving Fampharm strategic support in terms of shared services and local knowledge. The company benefits from Tender Group’s broader network in logistics and R&D. Additionally, its integration into a multi-industry conglomerate provides financial stability and long-term vision for growth.
Fampharm’s revival under Tender Group exemplifies the conglomerate’s broader mission: turning around companies in distress and fostering their development. By investing in pharmaceutical production, Tender Group also entered the healthcare sector, contributing to local employment and the availability of medicines. While details on current production volumes are scarce publicly, the commitment to build a new factory suggests a forward-looking expansion. This move could make Fampharm a significant player in the Balkan pharmaceuticals market in coming years, leveraging Tender’s capital and management expertise to ensure its success and compliance with international standards.
Schedule a consultation today!
Our team will answer your questions and talk you through potential next steps.
